CTOs on the Move

TAI Diagnostics

www.taidiagnostics.com

 
TAI Diagnostics, Inc. is a biotechnology company focused on providing a non-invasive and highly sensitive diagnostic test to monitor the health of transplanted organs in patients who have received solid organ transplants.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

TAI Diagnostics raised $10M on 01/08/2018

Similar Companies

Power Medical Interventions

Power Medical Interventions, Inc is a Mansfield, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ITH Healthcare

ITH Healthcare is a Forest Hills, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

II-VI

II-VI Incorporated, a global leader in engineered materials and optoelectronic components, is a vertically integrated manufacturing company that develops innovative products for diversified applications in the industrial, optical communications, military, life sciences, semiconductor equipment, and consumer markets. Headquartered in Saxonburg, Pennsylvania, the Company has research and development, manufacturing, sales, service, and distribution facilities worldwide. The Company produces a wide variety of application-specific photonic and electronic materials and components, and deploys them in various forms, including integrated with advanced software to enable our customers.

Perferx Optical Company Inc

Perferx Optical Company Inc is a Pittsfield, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide, with more than 100,000 implanted to date.